Evidence map›Paper›PMID 35355414›Full record

ReviewInfluenza and other respiratory viruses2022

Costs of seasonal influenza vaccination in South Africa.

Heather Fraser, Winfrida Tombe-Mdewa, Ciaran Kohli-Lynch, Karen Hofman, Stefano Tempia, Meredith McMorrow, Philipp Lambach, Wayne Ramkrishna, Cheryl Cohen, Raymond Hutubessy and 1 more

Abstract readReview
In one paragraph

Review in Influenza and other respiratory viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Costs of seasonal influenza vaccination in South Africa.Influenza and other respiratory viruses · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Heather FraserSAMRC Centre for Health Economics and Decision Science-PRICELESS SA, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-7100-571X
Winfrida Tombe-MdewaSAMRC Centre for Health Economics and Decision Science-PRICELESS SA, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Ciaran Kohli-LynchSAMRC Centre for Health Economics and Decision Science-PRICELESS SA, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Karen HofmanSAMRC Centre for Health Economics and Decision Science-PRICELESS SA, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Stefano TempiaInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Meredith McMorrowInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0001-6363-4033
Philipp LambachDepartment of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Wayne RamkrishnaCommunicable Disease Cluster, National Department of Health, Pretoria, South Africa.
Cheryl CohenSchool of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0003-0376-2302
Raymond HutubessyDepartment of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Ijeoma EdokaSAMRC Centre for Health Economics and Decision Science-PRICELESS SA, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Funding

NCEZID CDC HHS U50 CK000431World Health Organization 001
6 · The paper itself

Abstract

backgroundInfluenza accounts for a substantial number of deaths and hospitalisations annually in South Africa. To address this disease burden, the South African National Department of Health introduced a trivalent inactivated influenza vaccination programme in 2010.

methodsWe adapted and populated the WHO Seasonal Influenza Immunization Costing Tool (WHO SIICT) with country-specific data to estimate the cost of the influenza vaccination programme in South Africa. Data were obtained through key-informant interviews at different levels of the health system and through a review of existing secondary data sources. Costs were estimated from a public provider perspective and expressed in 2018 prices. We conducted scenario analyses to assess the impact of different levels of programme expansion and the use of quadrivalent vaccines on total programme costs.

resultsTotal financial and economic costs were estimated at approximately USD 2.93 million and USD 7.91 million, respectively, while financial and economic cost per person immunised was estimated at USD 3.29 and USD 8.88, respectively. Expanding the programme by 5% and 10% increased economic cost per person immunised to USD 9.36 and USD 9.52 in the two scenarios, respectively. Finally, replacing trivalent inactivated influenza vaccine (TIV) with quadrivalent vaccine increased financial and economic costs to USD 4.89 and USD 10.48 per person immunised, respectively.

conclusionWe adapted the WHO SIICT and provide estimates of the total costs of the seasonal influenza vaccination programme in South Africa. These estimates provide a basis for planning future programme expansion and may serve as inputs for cost-effectiveness analyses of seasonal influenza vaccination programmes.

Indexed as

Influenza, HumanInfluenza VaccinesCost-Benefit AnalysisHumansSeasonsSouth AfricaVaccinationInfluenza Vaccinescost analysishealth care economicsinfluenza vaccinepreventive health programmesSouth Africa

Identifiers

PMID35355414
PMCPMC9343325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.